Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain.
CONCLUSIONS: From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly and more effective) in comparison to vedolizumab, with relevant cost savings and similar QALY gains. PMID: 33615953 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 23, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer.
CONCLUSIONS: : At the current price, olaparib is not cost-effective when used with or without restriction by BRCA1/2 mutation status in Singapore, despite taking into account potential OS improvement over a long-time horizon. PMID: 33593205 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review.
Authors: Yuasa A, Yonemoto N, LoPresti M, Ikeda S Abstract INTRODUCTION: The kinds of costs included in cost-effectiveness analyses (CEAs) for vaccines, such as direct medical costs and indirect costs, may affect their outcomes. While some guidelines recommend inclusion of costs associated with productivity losses/gains, very little guidance is provided about the productivity elements to include and their calculation approach. Areas covered: We conducted a systematic review of CEAs for vaccines and vaccine programs published between 1 January 2010 and 19 November 2019 that included productivity costs using Medl...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study.
Conclusions: The high level of comorbidity and disease complexity in this patient group versus the general population is expected to correlate with a more intensive use of medical resources and costs. This study provides novel data to inform resource allocation and disease management decisions at the regional level. PMID: 33593235 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
CONCLUSION: Although trastuzumab biosimilar reduced the cost of the pertuzumab combination regimen, the ICER remained high and was not cost effective in Singapore's context. As pertuzumab contributed 80% of the overall combination treatment cost, price reductions for pertuzumab will be required to improve the cost-effectiveness of combination treatment to an acceptable level. PMID: 33595372 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 19, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost considerations of dermatological care in Jordan: a cross-sectional study.
This study aims to explore the cost estimation interest of patients with dermatological conditions, the influence of the cost on their drug use behaviour, and cost communication practices by dermatologists. Method: A cross-sectional study was conducted between October 2019 and January 2020 in Jordan. Logistic regression was conducted to explore the predictors of patient behaviour. Results: A total of 1,022 patients participated in the study. Around 27.7% of them reported that their dermatologist does not discuss the cost of medications with them. About 71.4% reported that it is important for them to receive cost estimates ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 12, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease.
Authors: Lee MT, Mahtta D, Alam M, Ullah W, Nasir K, Hanif B, Virani SS Abstract Introduction: As the leading cause of death globally, atherosclerotic cardiovascular disease (ASCVD) carries substantial cost burden for patients and the healthcare system. Although overall mortality rates have recently decreased in certain groups, such improvements were not observed in younger ASCVD patients. This review focuses on premature ASCVD and explores risk factors affecting this younger cohort of patients. Areas covered: We performed a literature search for studies assessing premature ASCVD, defined as ischemic heart disease ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 12, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.
Authors: Yu A, Huang E, Abe M, An K, Park SK, Park C Abstract INTRODUCTION: : Mutation-targeting and immuno-oncology drugs are revolutionizing the treatment of advanced non-small cell lung cancer (NSCLC). Cost-effectiveness analyses (CEA) of these drugs have been conducted using various analytical methods and cost-effectiveness thresholds. This systematic review provides a comprehensive summary of the available evidence. AREA COVERED: : PubMed, Embase, and Cochrane Library were used to select for CEA of targeted therapies for NSCLC in the U.S. published between 2008 and 2020. Among the 28 included studies, a ma...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 9, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Artificial intelligence in outcomes research: a systematic scoping review.
Authors: Graili P, Ieraci L, Hosseinkhah N, Argent-Katwala M Abstract Introduction: Despite the number of systematic reviews on how artificial intelligence is being used in different areas of medicine, there is no study on the scope of artificial intelligence methods used in outcomes research, the cornerstone of health technology assessment (HTA). This systematic scoping review aims to systematically capture the scope of artificial intelligence methods used in outcomes research to enhance decision-makers' knowledge and broaden perspectives for health technology assessment and adoption. Areas covered: The review ide...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 9, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
Authors: Godman B, Hill A, Simoens S, Selke G, Selke Krulichová I, Zampirolli Dias C, Martin AP, Oortwijn W, Timoney A, Gustafsson L, Voncina L, Kwon HY, Gulbinovic J, Gotham D, Wale J, Silva WCD, Bochenek T, Allocati E, Kurdi A, Ogunleye OO, Meyer JC, Hoxha I, Malaj A, Hierländer C, Sauermann R, Hamelinck W, Petrova G, Laius O, Langner I, Yfantopoulos J, Joppi R, Jakupi A, Greiciute-Kuprijanov I, Vella Bonanno P, Piepenbrink JH, de Valk V, Wladysiuk M, Marković-Peković V, Mardare I, Fürst J, Tomek D, Obach Cortadellas M, Zara C, Pontes C, McTaggart S, Laba TL, Melien Ø, Wong-Rieger D, Bae S, Hill...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 6, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A systematic review of cost-effectiveness analyses across the acute kidney injury landscape.
Authors: Suh K, Kellum JA, Kane-Gill SL Abstract INTRODUCTION: Acute kidney injury (AKI) is a complex and common condition associated with increased morbidity, mortality, and costs. Evidence from cost-effectiveness analysis (CEA) have targeted various aspects of AKI including detection with biomarkers, treatment with renal replacement therapy, and prevention when using contrast media. However, there has not been a systematic review of these studies across the entirety of AKI. Areas covered: PubMed, Embase, and Cochrane library were used to identify CEA studies that involved AKI from 2004 onwards. These studies comp...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 3, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis.
CONCLUSIONS: Of all DOACs, edoxaban 30 mg, apixaban 5 mg, and edoxaban 60 mg are the top 3 lowest NBI. Together with cost-effectiveness evidence, those DOACs should be considered to be listed in the National List of Essential Medicine in Thailand. PMID: 33504221 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 30, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review.
This study has been carried out through "Medline," "Scopus," "Cinhal," and "Web of Science" databases for all the papers published before January 24, 2020. Three independent authors have chosen the eligible studies based upon pre-set criteria of inclusion. Data collection, data items, and assessment of the risk of bias: the data extraction approach was chosen based on the Cochrane Methods. For data collection, the authors followed the recommendations from the COSMIN initiative. Study quality and risk of bias were assessed using the COSMIN Check List. EXPERT OPINION: : 119 publica...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 30, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Pharmacoeconomics of obesity in China: a scoping review.
This article reviewed publications retrieved from PubMed and Google Scholar during 2010-2020 on pharmacoeconomic studies related to overweight and obesity in China. We identified five cost-of-illness studies and four cost-effectiveness analyses of weight-loss interventions, including bariatric surgeries and a comprehensive intervention program. Expert opinion: There is a lack of pharmacoeconomic analyses of obesity in China. Existing studies have often taken the health system perspective without accounting for productivity loss. Cohort studies and studies based on electronic health records or claims data are needed to prov...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 27, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Challenges and opportunities in measuring pediatric quality of life: exemplified by research in pediatric gastroenterology.
Authors: Lamparyk K, Burkhart K, Buzenski J, van Tilburg MAL Abstract Introduction: Quality of life (QOL) is an important patient reported outcome measure (PROM). Assessment of QOL in children is challenging particularly because developmental age affects the accuracy of self-reports. Areas Covered: This paper gives an overview and expert opinion of the factors impacting quality assessment of pediatric QOL. Given this literature is vast, we focused on QOL measurement in pediatric gastroenterological conditions as an example, but the general principles apply across childhood chronic diseases. Child developmental stag...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 24, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Not cost-effective at zero price: valuing and paying for combination therapies in cancer.
Authors: Latimer NR, Towse A, Henshall C PMID: 33472440 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 23, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence.
Conclusion: Currently available well performed CEAs generally support the use of cemented and hybrid fixation for all age-groups relevant for THA and both genders. However, these findings were mainly based on a single database and depended on assumptions made in the studies' methodology. Issues discussed in this paper have to be considered and future work is needed. PMID: 33472442 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 23, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Incorporating patients' preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review.
The objectives of this review were therefore to summarize existing studies on cost-effectiveness analysis (CEA) with quality-adjusted life years (QALYs) and patients' preferences of DMTs for MS, and to discuss how to incorporate patients' preferences into the value assessment of DMTs. AREA COVERED: We reviewed previous systematic reviews and conducted further search until November 2020 for studies on CEA with QALYs and patients' preferences of DMTs for MS. We identified the outcomes that were assessed or valued in the CEA studies and the DMT attributes that were important to patients with MS. EXPERT OPINION: Our li...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 23, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Pattern of drug use in patients with psoriatic arthritis in Italy: study in a real-world setting.
Conclusion: This analysis provided insights on drug utilization patterns for PsA in an Italian real-world setting. Our results show that treatment regimen changes occur in a high proportion of PsA patients. PMID: 33472454 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 23, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model.
CONCLUSION: The difference between the drugs in terms of utility was minimal and the costs were the main factor that impacted the cost-utility ratio, which points to the benefits of price renegotiation for the efficient allocation of resources in the health system. PMID: 33474995 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 23, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

An early health technology assessment of 3D anatomic models in pediatric congenital heart surgery: potential cost-effectiveness and decision uncertainty.
Conclusion: For complex operations the implementation of anatomic models is likely to be cost-effective on a 15 year time horizon. For the right indication, these models thus provide a clinical advantage at an acceptable cost. PMID: 33475446 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 23, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population.
CONCLUSION: For valid and representative values of WTPQ, future researchers should therefore take into consideration various scenarios and investigate both health gain with certainty and uncertainty, health gain from both life length and quality of life, and different size of QALY gains. PMID: 33464926 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 20, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Performance-based risk-sharing agreements in renal care: current experience and future prospects.
Authors: Drummond M, Federici C, Busink E, Apel C, Kendzia D, Brouwer W Abstract INTRODUCTION: Performance-based risk-sharing agreements (PBRSAs), between payers, health care providers, and technology manufacturers can be useful when there is uncertainty about the (cost-) effectiveness of a new technology or service. However, they can be challenging to design and implement. AREAS COVERED: A total of 18 performance-based agreements were identified through a literature review. All but 2 of the agreements identified were pay-for-performance schemes, agreed between providers and payers at the national level. No exa...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 14, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017.
CONCLUSIONS: Even if previous drug approvals increased the cost of hospital discharges and other medical costs, the cost per life-year before age 85 gained in 2017 from those approvals could not have exceeded 1719 USD. The World Health Organization considers interventions whose cost per quality-adjusted life-year gained is less than per capita GDP to be highly cost-effective; New Zealand's per capita GDP in 2017 was 42,260 USD. PMID: 33412958 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 10, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE study.
Discussion: The study aims to reveal the unmet medical need, disease burden, resource utilization, and costs of PFIC, to raise awareness with policymakers and healthcare professionals, and provide support for the patient/caregiver community. As novel PFIC therapies recently emerged, this study will yield quantifiable data for health technology assessments. PMID: 33406947 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 9, 2021 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Direct medical costs of breast cancer in Jordan: cost drivers and predictors.
Conclusions: This analysis offers insight into costs, cost drivers, and resources utilization incurred by breast cancer patients in Jordan. Two major hospitals in Jordan can play a key informative role in future cost-effectiveness of breast cancer screening and therapeutic treatments in the different stages of cancer. PMID: 33353434 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 30, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Conducting economic evaluation based on basket clinical trial in the area of precision medicine.
Authors: Nosrati M, Nikfar S PMID: 33356657 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 30, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The impact of hypoglycaemia on healthcare costs: a modelling study from Chile.
CONCLUSIONS: The cost of hypoglycaemia represents a high proportion of the public health budget in Chile, being similar to those resources allocated to provide coverage of diabetic treatments through its universal health benefit plan. PMID: 33325312 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 18, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
Authors: Ruan Z, Shi H, Yue X, Wang Y, Liang M, Hu H Abstract INTRODUCTION: As a novel glucagon-like peptide-1receptor agonists (GLP-1 RA) for type 2 diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been assessed in several country settings. The authors' objective was to systematically review the existing pharmacoeconomic literature evaluating the cost-effectiveness associated with once-weekly semaglutide compared with other GLP-1 RAs and provide implications for further researches. AREAS COVERED: We conducted a systematic literature review of cost-effectiveness analysis (CEA) publish...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 17, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Authors: Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C Abstract Introduction: Many patients with major depressive disorder (MDD) do not achieve remission with their first antidepressant (AD), resulting in a high burden due to treatment failure. Vortioxetine is a valid treatment option for patients with MDD only partially responding to their first AD. Characterization of vortioxetine's potential benefits versus other approved treatments is important. Areas Covered: The cost-effectiveness of vortioxetine, including cognitive outcomes, was modeled in compariso...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 15, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic analyses of immune-checkpoint inhibitors to treat lung cancer.
Authors: Vergnenegre A, Chouaid C Abstract Introduction: Total lung-cancer-management costs are increasing dramatically. The widespread use of immune-checkpoint inhibitors (ICIs) explains this rise in large part and financially impacts healthcare systems. Economic assessment has been adapted to this new challenge. Areas covered: This review provides an overview of the economic literature on the use of ICIs to treat lung cancer. Numerous papers have been published over the last few years. Cancers analyzed were non-squamous non-small-cell lung cancer (NSCLC), squamous NSCLC, locally advanced NSCLC or small-cell lung ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 13, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
CONCLUSION: Benefits of the SC formulation over IV infusions is being converted to realistic monetary benefits for all providers and payers. PMID: 33275459 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 5, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
Conclusions: Policies that relate to the scope of reimbursement, time to reimbursement, and list price should be able to equally reflect patient accessibility and national health insurance finances, as well as the impact on industry as a whole. PMID: 33275463 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 5, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Assessment of the quality and trend of reporting of health economic evaluation research in India.
CONCLUSION: Inadequacy in reporting quality of health economic evaluation studies is evident. The trend revealed cost-effectiveness to be the most commonly performed type of analysis. PMID: 33249942 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 1, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Budget impact analysis of pneumococcal conjugate vaccines in Colombia.
CONCLUSION: These findings are potentially valuable for the selection of vaccines for their national immunization programs under conditions of budgetary constraint. PMID: 33249948 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 1, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer.
Conclusions: The associations between ESIBC characteristics and treatment-related QALY losses should be considered when evaluating breast cancer screening and treatment strategies. PMID: 33253057 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 1, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?
Authors: Wimo A PMID: 33241968 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 28, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system.
Conclusions: Polyarticular rheumatoid-factor positive and systemic JIA patients had the highest mean total annual medication costs, primarily attributable to biologicals. Costs varied considerably between subtypes, individuals, and over the treatment course. PMID: 33243033 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 28, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Assessing the effects of important factors and province heterogeneity on different quantiles of cost hospitalization.
CONCLUSION: More works must be done related to hospitalization cost and its consequences, since it is a matter of social life. To be exact, one should notice that provinces with hospitals involving high hospitalization costs may have households dealing with poverty. PMID: 33243035 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 28, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia.
Authors: Mowitz ME, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J, Sarda SP Abstract OBJECTIVE: To evaluate the prevalence of chronic respiratory morbidity (CRM) in preterm infants (born ≤28 weeks gestational age (GA)) and compare healthcare resource utilization and costs among infants with/without CRM, and with/without bronchopulmonary dysplasia (BPD). METHODS: Commercial claims data from the Truven MarketScan database were retrospectively analyzed. Included infants were born ≤28 weeks GA and admitted to a neonatal intensive care unit (January 2009-June 2016). Continuous insurance eligibility was r...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 27, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness of nivolumab in advanced melanoma: a drug review.
Authors: Specenier P Abstract Introduction: The immune checkpoint inhibitors, including nivolumab, and targeted agents have dramatically improved the outcome for patients with unresectable advanced melanoma. Areas covered: This is a narrative review of the published evidence on nivolumab in metastatic melanoma. Expert Opinion: In ipilimumab pre-treated patients (CheckMate 037), nivolumab was associated with a higher response rate and a longer duration of response when compared to chemotherapy. In previously untreated patients, nivolumab improves survival when compared to chemotherapy (CheckMate 066) or to ipilimuma...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 24, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Health-related quality of life in patients with chronic kidney disease.
Authors: Hussien H, Apetrii M, Covic A Abstract INTRODUCTION: In the last three decades, health systems have continued to pay increasing attention to the quality of life (QOL) due to definitional changes in the concept of health and disease. The health-related quality of life (HRQOL) in patients with chronic kidney disease (CKD) is significantly affected, regardless of the stage of CKD. AREAS COVERED: We attempt to thoroughly explore how CKD affects HRQOL domains with a quick primer on HRQOL assessment instruments in patients with CKD. Also, we pointed out the factors affecting HRQOL in patients with CKD as wel...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 21, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.
Authors: Diaby V, Almutairi RD, Babcock A, Moussa RK, Ali A Abstract INTRODUCTION: Treatment of human epithelial growth factor receptor 2 (HER2)-positive breast cancer has rapidly evolved over the past decades with the addition of trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine (T-DM1). These treatments have dramatically impacted the survival of HER2-positive metastatic breast cancer (mBC) patients. Nonetheless, these agents are associated with high price tags, begging the question, "Are treatments for HER2-positive metastatic breast cancer and associated metastases cost-effective"? AREA...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 21, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention.
CONCLUSION: The findings outline long-term clinical and economic benefits of expanding clinical pharmacist's roles in direct patient care services. PMID: 33213221 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 21, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cannabis use among Canadian adults with cancer (2007-2016); results from a national survey.
Authors: Abdel-Rahman O Abstract BACKGROUND: The current study aims to evaluate the rates and associations of cannabis use among Canadian adults with cancer (2007-2016). METHODS: Canadian Community Health Survey (CCHS) (2007-2016) was accessed and adult participants with who answered yes to the question "Do you have cancer?" and who have complete information about cannabis use were included. Multivariable logistic regression was used to clarify the factors associated with cannabis use. Another multivariable logistic regression analysis was used to evaluate the impact of cannabis use on suicidal ideati...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 21, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Patient associations and clinical oncology research: how much does a patient's voice really matter?
Discussion Although the current involvement of the Associations may have been somewhat underestimated, there is no doubt that much more can be done in terms of training and identification of common objectives between patients and professionals. PMID: 33201731 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 18, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Conclusion: Hydroxychloroquine/chloroquine and/or azithromycin use was associated with safety signals for QTp/TdP and their use should be monitored carefully. PMID: 33186061 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 17, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018).
CONCLUSION: The incidence of iCCA in Spain increased over the past years. The medical costs of iCCA per patient stabilized after 2008 but total costs are expected to increase if incidence continues to raise. PMID: 33161795 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 11, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

How can societal culture and values influence health and rehabilitation outcomes?
Authors: Fadyl JK PMID: 33167716 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 11, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
Conclusions: At a willingness-to-pay threshold of A$50,000/QALY, first-line osimertinib is not cost-effective compared with standard EGFR-TKIs in Australia based on the current published price. To achieve acceptable cost-effectiveness, the cost of first-line osimertinib needs to be reduced by at least 68.4%. PMID: 33151783 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 7, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research